[go: up one dir, main page]

AR108075A1 - Composición farmacéutica de hormona esteroide - Google Patents

Composición farmacéutica de hormona esteroide

Info

Publication number
AR108075A1
AR108075A1 ARP170100832A ARP170100832A AR108075A1 AR 108075 A1 AR108075 A1 AR 108075A1 AR P170100832 A ARP170100832 A AR P170100832A AR P170100832 A ARP170100832 A AR P170100832A AR 108075 A1 AR108075 A1 AR 108075A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
lipophilic
steroid hormone
progesterone
subject
Prior art date
Application number
ARP170100832A
Other languages
English (en)
Inventor
Jason D Legassie
Frederick D Sancilio
Thorsteinn Thorsteinsson
Philip B Inskeep
Peter H R Persicaner
Annette Shadiack
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of AR108075A1 publication Critical patent/AR108075A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica apta para administrar estradiol y progesterona a un sujeto que tiene la necesidad de ella, la composición farmacéutica comprende estradiol, progesterona, un sistema de surfactante lipofílico que comprende un primer surfactante lipofílico y un segundo surfactante lipofílico, donde el primer y segundo surfactantes lipofílicos son diferentes entre sí, un sistema de surfactante hidrofílico que comprende primeros y segundos surfactantes hidrofílicos, y un terpeno opcional, donde la composición farmacéutica está completamente o sustancialmente libre de aceites vegetales fraccionados. Reivindicación 18: Un método para tratar una enfermedad o condición asociada con niveles reducidos de estrógeno, el método comprende administrar a un sujeto que tiene la necesidad una composición farmacéutica de acuerdo con la reivindicación 1.
ARP170100832A 2016-04-01 2017-04-03 Composición farmacéutica de hormona esteroide AR108075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317359P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
AR108075A1 true AR108075A1 (es) 2018-07-11

Family

ID=59958436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100832A AR108075A1 (es) 2016-04-01 2017-04-03 Composición farmacéutica de hormona esteroide

Country Status (12)

Country Link
US (1) US20170281646A1 (es)
EP (1) EP3436023A4 (es)
JP (1) JP2019514852A (es)
KR (1) KR20180123165A (es)
AR (1) AR108075A1 (es)
AU (1) AU2017239679A1 (es)
BR (1) BR112018069877A2 (es)
CA (1) CA3019375A1 (es)
IL (1) IL261924A (es)
MX (1) MX2018011706A (es)
RU (1) RU2018133921A (es)
WO (1) WO2017173185A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2021081276A1 (en) * 2019-10-23 2021-04-29 Slayback Pharma Llc Stable pharmaceutical compositions containing estradiol and progesterone for oral administration
JP7649496B2 (ja) * 2020-01-08 2025-03-21 株式会社タフリーインターナショナル 冷感剤組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
GB2626266A (en) 2021-10-08 2024-07-17 Chemo Res S L Oral pharmaceutical compositions of progesterone and estradiol
WO2025178616A1 (en) * 2024-02-21 2025-08-28 Lipocine, Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5688740A (en) * 1996-04-30 1997-11-18 Ard Co., Pte. Ltd. Three-way catalyst for treating exhaust gases
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
JP2002304088A (ja) * 2001-04-09 2002-10-18 Ricoh Co Ltd 画像形成装置
SI1663161T1 (sl) * 2003-06-13 2015-05-29 Skendi Finance, Ltd. Akara Building Formulacija estradiola in progesterona s počasnim sproščanjem
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
KR101885244B1 (ko) * 2011-11-07 2018-08-06 삼성전자주식회사 유기 광전 소자 및 이미지 센서
KR20130055404A (ko) * 2011-11-18 2013-05-28 삼성전자주식회사 터치 디바이스에서 문자 입력 방법 및 장치
ES2885523T3 (es) * 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) * 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2951284A1 (en) * 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) * 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones

Also Published As

Publication number Publication date
KR20180123165A (ko) 2018-11-14
CA3019375A1 (en) 2017-10-05
IL261924A (en) 2018-10-31
JP2019514852A (ja) 2019-06-06
MX2018011706A (es) 2019-06-10
EP3436023A4 (en) 2019-10-16
EP3436023A1 (en) 2019-02-06
BR112018069877A2 (pt) 2019-02-05
AU2017239679A1 (en) 2018-10-18
WO2017173185A1 (en) 2017-10-05
RU2018133921A3 (es) 2020-05-12
RU2018133921A (ru) 2020-05-12
US20170281646A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
AR108075A1 (es) Composición farmacéutica de hormona esteroide
AR108073A1 (es) Composición farmacéutica de hormona esteroide, método
BR112016029338A2 (pt) creme transdérmico
MX2018010902A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
MX2017003037A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CO2018003424A2 (es) Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
CO2017007959A2 (es) Composiciones farmacéuticas para terapia combinada
BR112017014341A2 (pt) método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
CL2019000270A1 (es) Composición de cannabis.
PE20170242A1 (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas
AR059844A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
CO2018004821A2 (es) Ácidos nucleicos p-etoxi para formulación liposomal
MX2017014768A (es) Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
PE20181290A1 (es) Formulaciones y metodos para controlar el ciclo reproductivo y la ovulacion
MX386732B (es) Composición farmacéutica de corticosteroide soluble.
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
MX2018000021A (es) Composiciones multifasicas.
AR087790A1 (es) Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas
MX374702B (es) Composiciones que contienen extractos de curcuma longa y echinacea angustifolia que son utiles para reducir la inflamacion periferica y el dolor.
AR102374A1 (es) Limomeno: formulación y uso insecticida

Legal Events

Date Code Title Description
FB Suspension of granting procedure